Global In Vivo CRO Market Size study, by Type (Rodent, Non-Rodent), By GLP Type (Non-GLP, GLP Toxicology), By Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, Others) and Regional Forecasts 2022

Global In Vivo CRO Market Size study, by Type (Rodent, Non-Rodent), By GLP Type (Non-GLP, GLP Toxicology), By Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, Others) and Regional Forecasts 2022-2028.

Global In Vivo CRO Market is valued approximately USD 3.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 8.20% over the forecast period 2022-2028. Contract research organizations (CROs) that conduct biopharmaceutical research in vivo are known as in-vivo contract research organizations (CROs). With the increased popularity of biologics over small molecule medications, in-vivo CROs are gaining appeal. Rising demand for sophisticated pharmaceuticals, CROs implementing worldwide standards, and big pharmaceutical firms outsourcing R&D efforts to focus more on their core capabilities are driving market expansion. Furthermore, outsourcing is less expensive than performing an in-house study. This is anticipated to increase demand for in vivo CROs. The demand for a significant number of animal models has quickly expanded across the world in order to ensure the safety and efficacy of novel entities prior to human trials. As a result, the use of these animal models in research centres, which closely resemble the clinical manifestation of SARS-CoV-2, has bolstered market growth. The most prevalent cause of insulin resistance is obesity. According to a National Center for Biotechnology Information (NCBI) research published in 2019, roughly 39% of individuals globally are obese or overweight and at risk of acquiring Type 2 Diabetes Mellitus (T2DM). T2DM is characterized by a gradual reduction in beta-cell activity and insulin resistance. The epidemic has created extraordinary interruption in research and clinical studies over the previous two years. The COVID-19 pandemic was claimed to have interrupted 1,079 clinical studies financed by sponsors, partners, or CROs in November 2021. As of June 2021, oncology was the most affected therapeutic area, accounting for approximately a quarter of all interrupted studies. Clinical trial interruptions would have an influence on the in vivo studies industry. However, sponsors raised CRO outsourced trial spending in 2021 compared to the previous year, according to a recent Outsourcing-Pharma study. The majority of investments are going toward enhancing CRO assistance, particularly technology-based solutions to increase patient access and engagement. Furthermore, a rise in M&A activity by big and mid-sized CROs in 2021 would have a significant post-COVID-19 influence on market growth. Sygnature Discovery, for example, was sold to Rothschild's private equity arm, Five Arrows Principal Investment, and later to Keensight. This illustrates the enthusiasm of investors to invest in early-stage R&D CROs. Furthermore, a rise in M&A activity by big and mid-sized CROs in 2021 would have a significant post-COVID-19 influence on market growth. However, pharmaceutical companies' shifting preference for outsourcing clinical and preclinical trials impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global In Vivo CRO Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America emerged as the market leader. The existence of significant financing in this region influenced research efforts positively. For example, the United States has the largest per capita healthcare spending and funding from government agencies such as the National Institutes of Health (NIH), which promotes research. Over the projection period, Asia Pacific is expected to have the quickest CAGR. The region has a sizable treatment-naive population. It accounts for 53% of the world's urban population and has three times the yearly rate of urbanization as the West. These reasons are driving increase in clinical trials in Asia Pacific.

Major market player included in this report are:
Covance, Inc.
Theorem Clinical Research
WuXi AppTec, Inc.
inVentiv Health
Evotec (US), Inc.
Charles River Laboratories
American Preclinical Services, LLC.
GVK Biosciences Private Limited
Iris Pharma
Pronexus Analytical AB
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Rodent
Non-Rodent
By GLP Type:
Non-GLP
GLP Toxicology
By Indication:
Autoimmune/Inflammation Conditions
Pain Management
Oncology
CNS Conditions
Diabetes
Obesity
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global In Vivo CRO Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Covance, Inc.
Theorem Clinical Research
WuXi AppTec, Inc.
inVentiv Health
Evotec (US), Inc.
Charles River Laboratories
American Preclinical Services, LLC.
GVK Biosciences Private Limited
Iris Pharma
Pronexus Analytical AB

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.